...
首页> 外文期刊>Journal of experimental & clinical cancer research : >All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein
【24h】

All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein

机译:全反式维甲酸通过影响survivin和Bax蛋白的表达,抑制KIT活性并诱导胃肠道间质瘤GIST-T1细胞凋亡

获取原文
           

摘要

Background Imatinib, a selective tyrosine kinase inhibitor, has been used as a standard first-line therapy for irresectable and metastasized gastrointestinal stromal tumor (GIST) patients. Unfortunately, most patients responding to imatinib will eventually exhibit imatinib-resistance, the cause of which is not fully understood. The serious clinical problem of imatinib-resistance demands alternative therapeutic strategy. This study was conducted to investigate the effect of all-trans retinoic acid (ATRA) on GIST cell lines. Methods Cell proliferation was determined by trypan blue dye exclusion test. Western blot analysis was performed to test the expression of activated KIT, its downstream proteins, and apoptosis associated proteins. The cytotoxic interactions of imatinib with ATRA were evaluated using the isobologram of Steel and Peckham. Results and conclusion In this work, for the first time we have demonstrated that ATRA affected on cell proliferation of GIST-T1 and GIST-882 cell line through inhibition of cell growth in a dose dependent manner and induced apoptosis. High dose of ATRA induced morphologic change in GIST-T1 cells, rounded-up cells, and activated the caspase-3 protein. In further examination, we found that the ATRA-induced apoptosis in GIST-T1 cells was accompanied by the down-regulated expression of survivin and up-regulated expression of Bax protein. Moreover, ATRA suppressed the activity of KIT protein in GIST-T1 cells and its downstream signal, AKT activity, but not MAPK activity. We also have demonstrated that combination of ATRA with imatinib showed additive effect by isobologram, suggesting that the combination of ATRA and imatinib may be a novel potential therapeutic option for GIST treatment. Furthermore, the scracht assay result suggested that ATRA was a potential reagent to prevent the invasion or metastasis of GIST cells.
机译:背景技术伊马替尼(一种选择性的酪氨酸激酶抑制剂)已被用作不可切除和转移性胃肠道间质瘤(GIST)患者的标准一线治疗药物。不幸的是,大多数对伊马替尼有反应的患者最终都会表现出对伊马替尼的耐药性,其原因尚不完全清楚。伊马替尼耐药的严重临床问题需要其他治疗策略。进行这项研究以研究全反式视黄酸(ATRA)对GIST细胞系的影响。方法通过台盼蓝染料排斥试验测定细胞增殖。进行蛋白质印迹分析以测试活化的KIT,其下游蛋白和凋亡相关蛋白的表达。伊马替尼与ATRA的细胞毒性相互作用使用Steel和Peckham的等效线图进行了评估。结果与结论在这项工作中,我们首次证明ATRA通过以剂量依赖性方式抑制细胞生长并诱导细胞凋亡来影响GIST-T1和GIST-882细胞的细胞增殖。高剂量的ATRA诱导GIST-T1细胞,被舍入的细胞的形态变化,并激活caspase-3蛋白。在进一步的检查中,我们发现ATRA诱导的GIST-T1细胞凋亡伴随着survivin表达的下调和Bax蛋白的表达上调。此外,ATRA抑制GIST-T1细胞中KIT蛋白的活性及其下游信号AKT活性,但不抑制MAPK活性。我们还证明了ATRA与伊马替尼的组合通过等效线描记法显示出累加效应,表明ATRA与伊马替尼的组合可能是GIST治疗的一种新型潜在治疗选择。此外,筛查结果表明ATRA是防止GIST细胞侵袭或转移的潜在试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号